Kenneth Janzon
Direttore Tecnico/Scientifico/R&S presso Nordvacc Läkemedel AB
Patrimonio netto: 350 760 $ in data 30/06/2024
Profilo
Kenneth Janzon is the founder of Intervacc AB, which was founded in 2001.
He held the title of Independent Director at Intervacc AB.
Currently, Mr. Janzon is the Chief Technical Officer at Nordvacc Läkemedel AB.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
INTERVACC AB
1.51% | 30/06/2023 | 1 146 500 ( 1.51% ) | 350 760 $ | 30/06/2024 |
Posizioni attive di Kenneth Janzon
| Società | Posizione | Inizio |
|---|---|---|
Nordvacc Läkemedel AB
 Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Kenneth Janzon
| Società | Posizione | Fine |
|---|---|---|
| INTERVACC AB | Fondatore | 14/06/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| INTERVACC AB | Health Technology |
| Aziende private | 1 |
|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |
- Borsa valori
- Insiders
- Kenneth Janzon
